Estimating long term cost savings from treatment of Alzheimer's disease: A modelling approach

PharmacoEconomics

Volumn 16, Issue 2, 1999, Pages 165-174

  Fenn, Paul ^a   Gray, Alastair ^b  

^a NOTTINGHAM UNIVERSITY BUSINESS SCHOOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; COST CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL RATE;

ALZHEIMER DISEASE; CLINICAL TRIALS; COST SAVINGS; HUMANS; MODELS, ECONOMIC;

EID: 0032876922     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916020-00005     Document Type: Article

References (12)

1. Rogers SL, Farlow MR, Doody RS, Donepezil Study Group, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50 (1): 136-45
2. Rogers SL, Friedhoff LT, The Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Dementia 1996; 7 (6): 293-303
3. Davis KL, Thal LJ, Gamzu ER, The Tacrine Collaborative Study Group, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327 (18): 1253-9
4. Knapp MJ, Knopman DS, Solomon PR, The Tactine Study Group, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271 (13): 985-91
5. Souêtre E. Thwaites R, Yeardley H. Economic impact of Alzheimer's disease in the United Kingdom: cost of care and disease severity for non-instiutionalised patients with Alzheimer's disease. Br J Psychiatry 1999; 174: 51-5
6. Rösler M, Anand R, Cicin-Sain A, on behalf of the B303 Exclon® Study Group. Safety and efficacy of rivastigmine in patients with Alzheimer's disease: results of an international, 26-week, multicentre, randomised, placebo-controlled trial. BMJ 1999; 318: 633-8
7. Corey Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate): a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. In J Geriatr Pychopharmacol 1998; 1: 55-65
8. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
9. Fenn P, McGuire A, Phillips V, et al. Modelling programme costs in economic evaluation. J Health Econ 1996; 15 (1): 115-35
10. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer disease. Arch Neurol 1997; 54: 687-93
11. Gray A, Fenn P. Alzheimer's disease: the burden of illness in England. Health Trends 1993; 25 (1): 31-7
12. Taylor Nelson AGB. Monitoring alzheimer's disease in nursing homes. London: Taylor Nelson, 1997. Report no.: 046/911